# 18F-FDOPA PET in Neuroendocrine Tumours

> **NCT02431715** · — · NO_LONGER_AVAILABLE · sponsor: **British Columbia Cancer Agency**

## Conditions studied

- Thyroid Cancer, Medullary
- Carcinoid Tumor
- Pheochromocytoma
- Paraganglioma
- Insulinoma
- Neuroblastoma

## Interventions

- **DRUG:** [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)

## Key facts

- **NCT ID:** NCT02431715
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431715, "18F-FDOPA PET in Neuroendocrine Tumours". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02431715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*